Lantern Pharma Newsroom

Press Release: Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 P.m. ET

Dow JonesAug 1 20:06

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)

TipRanksMay 10 18:26

Lantern Pharma Analyst Ratings

BenzingaApr 25 18:42

Analysts' Opinions Are Mixed on These Healthcare Stocks: Lantern Pharma (LTRN), LifeMD (LFMD) and Calliditas Therapeutics (CALT)

TipRanksNov 9, 2023 20:02

EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

BenzingaAug 10, 2023 19:16

Lantern Pharma Analyst Ratings

BenzingaAug 10, 2023 19:15

Lantern Pharma (LTRN) Receives a Hold From H.C. Wainwright

TipRanksAug 10, 2023 18:25

Analysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Lantern Pharma (LTRN)

TipRanksJun 27, 2023 04:30

EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

BenzingaJun 27, 2023 02:37

EF Hutton Assumes Lantern Pharma at Buy, Maintains Price Target of $11

BenzingaMay 25, 2023 20:26

EF Hutton Reaffirms Their Buy Rating on Lantern Pharma (LTRN)

TipRanksMar 22, 2023 00:28

EF Hutton Sticks to Their Buy Rating for Lantern Pharma (LTRN)

TipRanksFeb 16, 2023 00:30

Lantern Pharma Analyst Ratings

Benzinga Analyst RatingsFeb 16, 2023 00:03

EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

Benzinga Real-time NewsFeb 16, 2023 00:02

EF Hutton Starts Lantern Pharma at Buy With $11 Price Target

MT NewswiresNov 1, 2022 22:04